IRS Logo
Print - Click this link to Print this page

Qualifying Therapeutic Discovery Project Grants for the State of Pennsylvania

The listings below represent the applicants that have been awarded a Qualifying Therapeutic Discovery Program Grant.

The project descriptions below were extracted from the applicant certification forms as submitted.

Pennsylvania $ 46,936,906.41
Applicant Name Project Name Grants Awarded for 2009 Grants Awarded for 2010
Absorption Systems LP The CellPort Technologies Project $ 146,819.00 $ 97,660.24
Acne E-Visit Acne E-Visit (Virtual Office Visit/Virtual Doctors Office)   $ 244,479.25
Adolor Corporation Delta Opioid Receptor Agonists, ADL5859 and ADL5747 $ 244,479.25  
Adolor Corporation Beloxepin Norepinephrine Reuptake Inhibitor/5HT Antagonist $ 244,479.25  
Adolor Corporation Entereg (alvimopan), a peripherally acting mu-opiod receptor agonist $ 244,479.25  
Adolor Corporation Peripherally acting mu opioid receptor antagonists $ 244,479.25  
Alung Technologies, Inc. Blood-oxygenating and carbon dioxide removal device, treating acute respiratory failure. $ 244,479.24  
Apogee Biotechnology Corporation New Drugs for Inflammatory Bowel Diseases $ 244,479.25  
Apogee Biotechnology Corporation New Topoisomerase Inhibitors to Treat Cancer $ 375.00 $ 86,737.50
Apogee Biotechnology Corporation Improvement of Liver Transplantation $ 3,000.00 $ 139,736.50
Apogee Biotechnology Corporation New Drugs for Lymphoma   $ 106,866.05
Apogee Biotechnology Corporation New Drugs Arthritis $ 90,742.54 $ 153,736.71
Aprecia Pharmaceuticals Company Aprecia Fast Metal medication (AFMM) $ 244,479.24  
Aptagen LLC Aptabodies $ 44,862.13 $ 85,044.66
Ascenta Therapeutics Inc AT-406, an oral, pan-IAP inhibitor (SMAC mimetic), for treatment of advanced malignancies $ 244,479.24  
Ascenta Therapeutics Inc AT-101, an oral, pan-Bcl-2 family protein inhibitor, for treatment of advanced malignancies $ 244,479.24  
Assistive Technology Products, Inc. HydroCare $ 36,464.50 $ 208,014.75
Aviana Molecular Technologies, LLC Cost Effective Point of Care Diagnostic Platform Technology $ 32,036.50 $ 118,934.00
Avid Radiopharmaceuticals Inc. Application of Florbenazine-F18 in diagnosis of Parkinson's Disease and Diabetes $ 244,479.25  
Avid Radiopharmaceuticals, Inc. Application of Florbetapir-F18 in diagnosis of Alzheimer's Disease $ 244,479.25  
Azevan Pharmaceuticals, Inc. A New Drug for Depression $ 244,479.25  
Bio Capture LLC Improved Stem Cell Separation for Cell Therapeutics   $ 191,024.50
BIOFLUID TECHNOLOGY, INC NON-INVASIVE URETHRO-CYSTOMETER   $ 244,479.24
Biometric Imaging Inc Metrobolic Imaging in 3 Dimensions Apparatus and Clinical Trials $ 95,246.50 $ 149,232.74
BioNanomatrix Inc Development of an advanced genome analysis system for use in research and diagnostics $ 244,479.24  
Blue Belt Technologies, Inc Precision Freehand Sculptor (PFS) $ 244,479.24  
BroadSources, Inc. Development of Dual MetAP2 and Sirt1 Inhibitors as Anti-Cancer Drugs $ 2,610.00 $ 114,480.50
Caliber Therapeutics, Inc. TADD $ 244,479.25  
Cardiokine Inc Lixivaptan $ 244,479.25  
Carmell Therapeutics Corporation REPAIR bone putty $ 95,028.50 $ 149,450.74
Carmell Therapeutics Corporation REPAIR tendon repair scaffold $ 16,374.50 $ 142,726.50
Catherex Inc. Clinical development of G207 oncolytic HSV cancer therapy for brain cancer.   $ 212,433.00
Catherex Inc. Clinical development of NV1020 oncolytic HSV cancer therapy for bladder cancer.   $ 232,558.00
Celsense, Inc. The Development of Perfluorocarbon MRI Cell Tracking Reagents $ 244,479.24  
Cernostics, Inc Tissue Systems Pathology for Barrett's Esophagus Testing $ 115,894.81 $ 128,584.43
COGNITION THERAPEUTICS, INC. DISCOVERING AND DEVELOPING SMALL MOLECULE DISEASE-MODIFYING THERAPEUTICS FOR ALZHEIMER'S DISEASE $ 244,479.25  
Cohera Medical, Inc. Clinical Trial of Preventative Therapy for Post-surgical Seroma $ 244,479.24  
CONREX PHARMACEUTICAL CORPORATION Project RPM $ 129,367.00 $ 115,112.24
Controlled Chemicals, Inc. BACE 1 Inhibitors for Delaying the Onset and Progression of Alzheimer's Disease $ 56,936.70 $ 80,000.00
COR Innovations Preventing Heart Failure $ 113,000.00 $ 131,479.25
Cutanea Life Sciences, Inc. The Development of Omiganan Topical Gel for Atopic Dermatitis $ 244,479.25  
Cytokine Pharmasciences, Inc CPSI-2364 A Small-Molecule Inhibitor of Cytopkine Production $ 244,479.24  
Cytokine Pharmasciences, Inc. The MISODEL VAGINAL INSERT   $ 244,479.24
Cytokine Pharmasciences,Inc CPSI-306 A SMALL MOLECULE INHIBITOR OF IVIF $ 141,943.50 $ 102,535.75
Diamyd Incorporated NP2 Chronic Pain Therapy $ 244,479.25  
Diasome Pharmaceuticals, Inc HDV-Insulin $ 244,479.24  
Digestive Care Inc Pancreatic Cancer Clinical Trial and Complete NDA Requirements $ 244,479.24  
Discovery Laboratories, Inc. Aerosurf® (aerosoilized LUCINACTANT) for prevention of neonatal RDS $ 244,479.25  
Dynamis Therapeutics, Inc Inhibitors of FN3K Enzyme as a treatment for Diabetic Complications $ 115,528.00 $ 128,951.25
EAGLE VISION PHARMACEUTICAL CORP SEEMORE: NOVEL INTRACELLULAR MOLECULAR ENHANCEMENT FOR MAGNETIC RESONANCE IMAGING $ 79,637.00 $ 81,792.00
Enantigen Therapeutics Inc Novel Antimicrobial Agents Targeting Drug Resistant Bacterial Biofilms $ 28,060.00 $ 10,347.50
Enantigen Therapeutics, Inc Development of a therapy for Dengue Virus infection $ 72,652.50 $ 32,358.50
Eusa Pharma (USA) Inc Capromab Pendetide Scanning-Optimizing Patient Selection $ 32,786.19 $ 25,002.08
Eusa Pharma (USA), Inc Samarium SM-153 Combined with Docetaxel $ 137,957.66 $ 68,302.99
EUSA PHARMA (USA), INC. PROSTASCINT FOR BRACHYTHERAPY IN LOCALIZED PROSTATE ADENOCARCINOMA $ 70,088.95 $ 55,489.78
EUSA PHARMA (USA), INC. CAPHOSOL FOR THE REDUCTION OF MUCOSITIS IN HEAD AND NECK CANCER PATIENTS $ 244,479.25  
EyeIC Incorporated MatchedFlicker: A Novel Tool for Early Detection of Important Eye Diseases $ 244,479.25  
Falcon Genomics, Inc. The Cancer BioChip System $ 76,417.50 $ 168,061.75
FemmePharma Global Healthcare, Inc Use of Dermodel ™ Danazol for the Treatment of Fibrocystic Breast Disease (FBD) $ 244,479.25  
FemmePharma Global Healthcare, Inc. PARDEL Oxybutynin, a Novel. Patented Delivery for the Treatment of Interstitial Cystitis in $ 244,479.25  
Fibrocell Technologies, Inc. Platform Autologous Fibroblast Therapy $ 244,479.24  
FLEXUSPINE INC. Flexuspine FSU (Functional Spinal Unit) Total Spinal Segment Replacement $ 244,479.25  
Formula Pharmaceuticals, Inc WT-1 vaccine   $ 244,479.25
Fox Chase Chemical Diversity Center Inc Porphobilinogen Synthase Assembly-State Regulators to Treat Infectious Disease. $ 49,532.00 $ 102,250.50
Fox Chase Chemical Diversity Center Inc. Small Molecule Therapeutics for Botulinum Neurotoxin A. $ 56,019.50 $ 156,958.00
Fox Chase Chemical Diversity Center, Inc. Riluzole Prodrugs for Melanoma and ALS   $ 26,875.00
Galactica Pharamceuticals, Inc. Development of Galactica's RAGE-Ig fusion protein through completion of a first human proof-of-concept clinical trial in diabetic macular edema. $ 94,189.50 $ 18,200.00
Galleon Pharmaceuticals Inc Postoperative Pain Prophylaxis $ 244,479.24  
Galleon Pharmaceuticals, Inc Apnea of Prematurity $ 33,004.56 $ 211,474.68
Galleon Pharmaceuticals, Inc. Prevention of Opiate Induced Respiratory Depression $ 244,479.24  
Gemin X Pharmaceuticals US, Inc Obatoclax $ 244,479.24  
Genisphere LLC Improvement of RNA amplification methods for use in molecular diagnostics/progostics $ 12,668.50 $ 115,422.50
Genisphere, LLC Improvement of microRNA labeling technology for use in molecular diagnostics/prognostics $ 34,953.00 $ 63,155.00
Gentis, Inc Polymerizabel Reverse Emulsions as a Platform Technology $ 244,479.25  
GLYCADIA, Inc Clinical Development of NCE GLY-230 to Treat or Prevent Complications of Diabetes $ 200,620.00 $ 43,859.24
HALARE, LLC ASTHMA TREATMENT- PRODUCT DEVELOPMENT AND TRIALS   $ 244,479.24
Hemispherx Biopharma Inc Ampligen $ 244,479.25  
Hemispherx Biopharma, Inc. Alferon N Injection $ 244,479.25  
HRP Imaging Technologies, LLC Development of 3-D gamma camera for high-resolution imaging intra-oro   $ 232,814.00
Hybridyne Imaging Technologies, Inc. Development of Compact Gamma Camera for Detection of Prostate Carcinoma   $ 56,479.25
IMC Biotechnology Novel Small Molecule Therapy for ANCA Associated Vasculitis $ 15,641.86 $ 15,000.00
Imiplex LLC Engineered Protien for Cancer and Alzheimers Disease Diagnostics $ 6,170.04 $ 50,025.52
IMMUNOME, INC. Development of a native human antibody-based therapeutic for C. difficile infection. $ 116,847.00 $ 127,632.24
Immunomic Therapeutics Inc Immunotherapeutic Vaccine for Treatment of Cedar Pollenosis.   $ 244,479.25
Immunotope Inc Multiepitope therapeutic vaccine for drug resistant ovarian cancer $ 77,830.00 $ 46,014.50
Immunotope Inc Development of "ImmuChip" an Early Diagnostic Test for Ovarian and Prostate Cancer   $ 157,720.50
Immunotope Inc Multieptipe Universal Dengue virus vaccine $ 24,081.50 $ 35,377.00
Immunotope Inc Synthetic Nanoparticle based Universal nfluenza Vaccine   $ 40,269.50
Immunotope, Inc. Hepatocellular carcinoma (HCC) diagnostics defined by fucosylated serum biomarkers $ 242,468.50 $ 2,010.75
InfaCare Pharmaceuticals Corp Stanate $ 244,479.25  
InfraRed Imaging Systems, Inc (INRIS) Vascular Viewer $ 157,520.03 $ 86,959.21
InfraScan, Inc. Infrascanner $ 159,484.11 $ 84,995.13
Inovio Pharmaceuticals Inc SYNCON ™ Vaccines for emerging infectious disease $ 244,479.25  
INOVIO Pharmaceuticals Inc. Clinical Development of a novel Therapeutic Vaccine for Cervical Cancer $ 244,479.25  
INOVIO PHARMACEUTICALS, INC DEVELOPMENT OF A UNIVERSAL INFLUENZA VACCINE $ 244,479.25  
INRange Systems, Inc INRange Electronic Medication Management Assistant (EMMA) $ 244,479.25  
Insituvue Inc. Sonic Flashlight   $ 244,479.25
Integral Molecular Inc Isolating Antibodies and Mapping Immune Responses to Viral Vaccines and Pathogens $ 179,877.81 $ 64,601.44
Integral Molecular Inc Molecular Determinants of Drug and Antibody Recognition $ 144,693.13 $ 99,786.12
Integral Molecular Inc Detection of Dengue Neutralizing and Enhancing Antibodies $ 244,479.25  
Integral Molecular, Inc Influenza Drug Development $ 104,554.83 $ 123,145.24
Integrated Technologies & Services International LLC Breast Cancer Diagnostic Test $ 90,015.78 $ 92,969.65
Iroko Pharmaceuticals, LLC Diclofenac $ 244,479.25  
Iroko Pharmaceuticals, LLC Indomethacin $ 244,479.25  
Iroko Pharmaceuticals, LLC Naproxen $ 244,479.25  
JDP Therapeutics Inc JDP-205 $ 26,972.00 $ 217,507.25
Jenrin Discovery Inc Peripheral-Selective CB1 Antagonists as a New treatment Option for Metabolic Diseases $ 244,479.25  
Keystone Biologics, Inc. Ulcerative Colitis   $ 244,479.25
Keystone Nano Inc. NanoJackets $ 244,479.25  
Kibow Biotech, Inc Further drug-Like Clinical Validation for Kidney Health Probiotic Supplement Product $ 36,916.50 $ 207,562.74
Knopp Neurosciences Inc KNS-760704 for treatment of ALS (Amyotrophic Lateral Sclerosis) $ 244,479.25  
Lazarus Therapeutics, Inc. GM1 Ganglioside for Parkinson's Disease $ 150,177.50 $ 94,301.75
LifeSensors, Inc Myostatin pro-peptide and regulation of muscle growth: A Novel Therapeutic Approach $ 244,479.25  
LifeSensors, Inc. Biomarker Discovery:  Ubiquitin Pathway Protein Microarrays $ 231,140.06 $ 13,339.19
Lipella Pharmaceuticals, Inc. Intravesical Liposomal Therapy $ 103,000.16 $ 141,479.08
Locus Pharmaceuticals, Inc THERAPEUTICS TO ADDRESS CHEMOTHERAPY RESISTANCE $ 244,479.25  
Longevity Biotech, Inc VIP Hybridtide agonist for the treatment Small Cell Lung Cancer   $ 30,967.51
Longevity Biotech, Inc VPAC1 Hydridtide antagonist for the treament  Colon Cancer   $ 30,967.51
Longport, Inc. Clinical and Finacial Impact of High Frequency Ultrasound $ 17,804.57 $ 18,329.56
Marillion Pharmaceuticals Inc Novel Diagnostic & Therapeutic Agency for Hormone Refractory Prostate Cancer $ 131,820.15 $ 6,000.00
Marillion Pharmaceuticals Inc Phase II study of a pilocarpine buccal insert for the treatment of dry mouth   $ 35,000.00
Mauna Kea Technologies Inc Cellvizio- probe based Confocal Laser Endomicroscopy (pCLE) system $ 244,479.25  
Melior Discovery, Inc MLR-1362 $ 149,799.48 $ 74,220.67
Melior Discovery, Inc MLR-1023 $ 244,479.24  
Midway Pharmaceuticals, Inc Development of MDY-1001 to Prevent Radiation Enteritis and Other GI Diseases $ 46,690.50 $ 6,163.00
Molecular Detection , Inc Diagnosis Test for the Identification of MRSA Carriers as Part pf Hospital Based Screening   $ 244,479.24
Molecular Targeting Technologies, Inc Cardiac Imaging With tc-Glucarate $ 234,444.50 $ 10,034.74
Neograft Technologies, Inc. Angioshield Vascular Reinforcement for Saphenous Veins $ 244,479.25  
Neotropix, Inc NTX-010 $ 244,479.24  
Neuro Kinetics Inc Sports Concussion Project $ 26,950.00 $ 217,529.24
NeuroDX Development LLC ShuntCheck, Thermal Dilution Device for Detecting CSF Shunt Failure in Hydrocephalus $ 20,817.26 $ 78,017.43
NEUROINTERVENTIONAL THERAPEUTICS, INC. D/B/A NEUROINTERVENTIONS, INC. NIT ISCHEMIC STROKE INTERVENTION SYSTEM $ 182,020.00 $ 62,459.24
Neuronetics, Inc. NeuroStar Transcranial Magnetic Stimulation (TMS) Therapy System $ 244,479.25  
Nitric Bio Therapeutics, Inc. Treatment of Tinea Pedis with Gaseous Nitric Oxide (gNO) $ 244,479.24  
Nitric BioTherapeutics, Inc. Treatment of Onychomycosis through lontophoretic Delivery of Terbinafine $ 38,706.50 $ 205,772.74
Novira Therapeutics Development of novel and first in class antiviral therapeutic for HIV targeting viral assembly $ 146,194.34 $ 98,284.91
Novira Therapeutics Inc Development of a novel, first-in-class antiviral for Hepatitis B virus targeting viral assembly $ 82,447.50 $ 104,873.00
Numoda Biotechnology Inc. Vitreosolve   $ 244,479.25
NuPathe Inc Zelrix $ 244,479.25  
NuPathe Inc NP202   $ 161,000.00
NuPathe Inc NP201:Novel treatment for the syptomatic treatment of Parkinson's disease $ 177,100.00 $ 67,379.25
Nuron Biotech Inc Nuron 200 recombinant human Epidermal Growth Factor   $ 244,479.24
Nuron Biotech, Inc BaroFeron (Interferon beta-1b) for subcutaneous injection   $ 244,479.24
Onconova Therapeutics, Inc. ON01910Na Therapeutic $ 244,479.24  
Onconova Therapeutics, Inc. Anti-MPD Therapeutic $ 244,479.24  
Onconova Therapeutics, Inc. ON13105 Anti- Cancer Therapeutic $ 188,572.21 $ 55,907.03
Onconova Therapeutics, Inc. Ex-Rad radioprotectant $ 244,479.24  
OPTINOSE US, INC Further Deveopment of a device to deliver pharmaceutical products.   $ 244,479.25
Optinose US, Inc. Further development of a device to deliver pharamaceutical products.   $ 244,479.25
Othera Pharmaceuticals, Inc OT-551: A potential First-Ever Therapeutic for Dry AMD $ 244,479.25  
Othera Pharmaceuticals, Inc. OT-440: A Novel Neuroprotectant Therapeutic for Glaucoma $ 157,301.00 $ 11,340.00
Penn-Century Inc. Aerosolized delivery of Cisplantin:an effective, less toxic, less costly lung cancer treatment $ 101,237.26 $ 143,241.99
Pharmabridge Inc Novel HBV Therapeutic with Potential for Treatment of Drug-Resistant Infection $ 91,944.62 $ 44,553.20
PhaseBio Pharmaceuticals Inc. PB1023 (GLP-1-ELP-120) a Novel Long Acting GLP-1 Analog for the Treatment of T2DM $ 244,479.24  
PhaseBio Pharmaceuticals Inc. PB1120 (VIP-ELP-120) Novel Long Acting VIP for Resistant and Uncontrolled Essential HTN $ 131,194.00 $ 113,285.24
Piezo Resonance Innovations, Inc Miniaturized, Hi-Performance, MRI-Compatible, Bioinstrumentation Ultrasonic Motor Platform $ 139,711.00 $ 75,884.00
Piezo Resonance Innovations, Inc Active Medical Devices for Clearing Feeding Tubes In-situ $ 71,629.00 $ 150,937.00
Pinmed Inc A low -cost, personalized cardiorespiratory profiling and monitoring system $ 59,875.51 $ 53,765.14
PolyMedix, Inc Synthetic Defensin Biomimetics for Use in treating Infectious Diseases $ 244,479.25  
PolyMedix, Inc. Synthetic Anticoagulant Reversing Agent $ 244,479.25  
Precision Therapeutics, Inc. Extension of application of ChemoFx® Drug Response Marker $ 244,479.24  
Prescient Medical, Inc. vPredict Optical Diagnostic Catheter $ 244,479.24  
Prime Synthesis, Inc. Hybrid Support Technology $ 115,877.44 $ 128,601.80
Progenra Inc USP20/33 inhibitor for treatment of renal cancer $ 244,479.25  
Progenra Incorporated USP7 inhibitor for treatment of multiple myeloma $ 244,479.24  
Progenra, Incorporated inhibitors of MuRF-1 for muscle wasting $ 244,479.24  
Promedior Inc Development of PRM-151 for the treatment and prevention of fibrosis $ 244,479.25  
Pulsar Informatics Inc System to individually tailor therapeutics delivery with fewer visits to physician's office. $ 174,902.50 $ 69,576.75
QR Pharma Inc POSIPHEN $ 183,376.00 $ 61,103.25
Ras Therapeutics, Inc A Phase 1 clinical trial utilizing a targeted therapy for the treatment of pancreatic cancer $ 53,361.50 $ 104,785.00
Recro Pharma, Inc Non-IV dexmedetomidine for pain $ 244,479.25  
RedPath Integrated Pathology Inc Metastic vs. Primary Cancer (MvPDx) $ 183,075.50 $ 61,403.75
RedPath Integrated Pathology Inc PathFinderTG Pancreatic Cyst Assay $ 244,479.25  
Richard J. Arnott Add-on device for treatment of various respiratory conditions via metered variable pressure. $ 53,244.24 $ 127,688.25
Russell Biotech Inc. Ferromagnetic Dense Particle-based Early Diagnostic Test for Liver Cancer. $ 55,691.00 $ 5,325.00
Saladax Biomedical Inc Paciliaxel Dose Management Assay $ 103,686.00 $ 140,793.24
Saladax Biomedical, Inc Docetaxel Dose Management Assay $ 106,285.50 $ 138,193.74
Saladax Biomedical, Inc Imatinib Dose Management Assay $ 112,542.00 $ 131,937.24
Saladax Biomedical, Inc Alzheimer's Disease Biomarker Assays   $ 244,479.24
Seneb BioSciences, Inc Glycolipid Replacement Therapy as a Treatment for Parkinson's Disease   $ 28,753.40
Separation Design Group, LLC Light Weight PORTABLE Medical OXYGEN CONCENTRATOR (POC) $ 144,533.42 $ 95,322.28
SERENITY PHARMACEUTICALS LLC SER-120 $ 189,813.50 $ 54,665.75
Shifa Biochemical Corporation Novel Antithrombotic Drugs $ 23,602.84 $ 10,104.97
Shifa Biomedical Corporation Drugs for Hormone Refractory Prostate Cancer $ 35,163.69  
Shifa Biomedical Corporation Novel Modulators of Cholesterol Metabolism $ 198,898.33 $ 45,580.91
Solixia Inc. Targeted Padiotherapy of Ovarian Cancer with a Novel, High Payload Radioligand $ 4,015.88 $ 2,218.83
Sonitu Pharmaceuticals LLC Small molecule inhibitor of PI-3AKt/mTOR for treatment of hepatocellular carcinoma $ 21,153.00 $ 22,516.50
Sonitu Pharmaceuticals LLC Broad spectrum antidote/vaccines for treatment of Staphylococcal & Streptococcal Disease   $ 60,425.00
Specialty Pharmaceutical Products, L.L.C. Advanced Therapeutic SPP Systems $ 143,722.91 $ 35,316.26
SpectraGenetics LLc Epitope-tagged Transcription Factor for Epigenetic Signatures in Human Cancer $ 71,581.00 $ 107,908.50
Stemnion, inc Commercialization-Stemnion Proprietary cell technology platform for regenerative medicine $ 244,479.24  
Tarsa Therapeutics, Inc. Oral recombinant calcitonin for prevention & treatrment of post menopausal oteoporosis $ 244,479.24  
TegoPharm Corporation Non-covalent masking of therapeutic monocional antibodies to enhance the therapeutic index $ 7,500.00 $ 20,000.00
Tengion, Inc Tengion Neo-Kidney Augment (NKA) $ 244,479.25  
Tengion, Inc. Tengion Neo-Bladder Augment (NBA) $ 244,479.24  
Tengion, Inc. Tengion Neo-Esophagus Augment (NEA) $ 68,457.06 $ 166,049.83
Tengion, Inc. Tengion Neo-Urinary Conduit (NUC) $ 244,479.25  
TenX Biopharma Inc Development of Zanolimumab, a Fully Humanized Anti CD4 Monoclonal Antibody for Cancer $ 244,479.25  
Tetralogic Pharmaceuticals Corporation Treatment of Traumatic Brain Injury using TL14077, a Selective Inhibitor of RP1 Kinase $ 244,479.24  
TetraLogic Pharmaceuticals Corporation Treatment of Cancer using a First in Class, Selective IAP Antagonist, TL32711 $ 244,479.24  
Thar Pharmaceuticals, Inc Thar Pharmaceuticals:IV to Oral Zoledronic Acid $ 211,486.50 $ 32,992.75
Thermal Therapeutic Systems, Inc Perfusion system to heat, circulate and monitor chemotherapeutic solutions $ 244,479.24  
Third Eye Diagnostics, Inc. CerePress $ 51,095.00 $ 193,384.24
Topaz Pharmaceuticals, Inc. Novel and Safe Treatment of Head Lice Infections in Children and Adults. $ 244,479.24  
Toph Biologics Novel Reagents For The Diagnosis of Cancer specific Glycoforms.   $ 31,812.50
Transdermal Specialties, Inc Ultrasonic Drug delivery System $ 244,479.25  
Transmolecular, Inc TM601 Tumor Targeting Project $ 244,479.25  
Trevena, Inc Signal selective kappa opioid receptor ligand for the management of chronic pain $ 244,479.25  
Trevena, Inc. Signal selective mu opioid receptor ligand for the management of acute and chronic pain $ 244,479.25  
Trevena, Inc. Signal selective angiotensin receptor ligand for the treatment of acute failure $ 244,479.25  
TREVENTIS Corporation Amyloid Oligomer-Specific Antagonists as a Therapeutic for Alzheimer's Disease $ 33,837.50 $ 210,641.74
Varinel, Inc. Multifunctional Drugs Treating Neurodegenerative Diseases and Wound Healing   $ 48,311.50
VascularStrategies LLC Development of high-throughput assay for measurement of global cellular cholesterol efflux   $ 46,450.00
VaxForm, LLC Development of protein fusion vaccine protective against Streptococcus Pyogenes   $ 5,498.53
Vicept Therapeutics, Inc. V-101 $ 244,479.24  
Vironika,LLC Development of Inhibitors of Latent Epstein-Barr Virus Infection $ 16,552.41 $ 118,226.61
VIROPHARMA INCORPORATED NON-TOXIGENIC COLSTRIDIUM DIFFICILE (NTCD) $ 244,479.25  
Vitae Pharmaceuticals Inc Development of LXR Agonists for the prevention and Treatment of Atherosclerosis $ 244,479.24  
Vitae Pharmaceuticals Inc Development of BACE Inhibitors for the Treatment of Alzheimer's Disease $ 244,479.24  
Vitae Pharmaceuticals Inc Development of 11Beta-HSD1 inhibitors for Treatment of Diabetes and Metabolic Syndrome $ 244,479.24  
Vitae Pharmaceuticals Inc Development of Renin inhibitor for Treatment of Hypertension and Chronic Kidney Disease $ 244,479.24  
Vytrace Corporation Continuous glucose monitor for the acute care setting $ 122,501.00 $ 95,511.00
Xylos Corporation Biocellulose technology solutions for the treatment, repair, and replacement of human tissue $ 244,479.25  
Yaupon Therapeutics, Inc. Evaluation of Clearazide for CTCL $ 244,479.24  
YM Biosciences USA Inc. Nimotuzumab $ 244,479.25  
YM BioSciences USA Inc. CYT997   $ 244,479.25
ZaBeCor Pharmaceuticals, LLC Excellair: A New Frontier in the Treatment of Asthma and Inflammation. $ 244,479.24  

References/Related Topics

Page Last Reviewed or Updated: 26-Mar-2014